These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37129156)

  • 1. Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study.
    Wang C; Wang Z; Zhao Y; Wang F
    J Gastric Cancer; 2023 Apr; 23(2):328-339. PubMed ID: 37129156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant PD-1 inhibitor plus apatinib and chemotherapy versus apatinib plus chemotherapy versus chemotherapy alone in patients with locally advanced gastric cancer.
    Xiong H; Li Y
    Am J Cancer Res; 2023; 13(8):3559-3570. PubMed ID: 37693166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apatinib plus chemotherapy versus chemotherapy alone as neoadjuvant therapy in locally advanced gastric carcinoma patients: a prospective, cohort study.
    Sun Y; Fan Y; Ye Z; Dong J; Zhang L; Peng Y
    Ir J Med Sci; 2023 Jun; 192(3):1033-1040. PubMed ID: 35819743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma.
    Wang Z; He T; Yu D; Qin X; Geng A; Yang H
    Exp Ther Med; 2022 Oct; 24(4):625. PubMed ID: 36160880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study.
    Xu C; Xie X; Kang N; Jiang H
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):4091-4099. PubMed ID: 36042044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients.
    Pan D; Liu D; Liang L; Shen T; Shi C; Qin H
    Front Oncol; 2022; 12():863392. PubMed ID: 35664730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial.
    Pan L; Tian Y; Wang K; Tang J; Liu J; Zhang J; Wang M; Liu J; Xu H; Chen X
    J Gastrointest Oncol; 2022 Dec; 13(6):3300-3313. PubMed ID: 36636043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study.
    Chen S; Wei H; Zhao W; Jiang W; Ning R; Zhou S; Tan L; Wang H; Su C; He J; Zeng A; Zhao Y; Yu Q
    Front Immunol; 2022; 13():1059995. PubMed ID: 36569915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer.
    Hou X; Shi X; Luo J
    Oncol Lett; 2022 Jul; 24(1):215. PubMed ID: 35720491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer.
    Zhang Y; Zhang B; Yang J; Zhang J; Zhang W
    Cancer Manag Res; 2021; 13():2279-2286. PubMed ID: 33732020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
    Zheng Y; Wang Z; Yan C; Yan M; Hou Z; Zheng R; Zhu Z; Li C
    Ann Transl Med; 2020 Dec; 8(24):1684. PubMed ID: 33490196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of camrelizumab plus apatinib compared to apatinib monotherapy as third-line or above therapy for metastatic colorectal cancer patients: A retrospective cohort study.
    Li C; Yu F; Xu W
    J Clin Pharm Ther; 2022 Dec; 47(12):2325-2334. PubMed ID: 36495117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.
    Li LH; Chen WC; Wu G
    Dis Markers; 2022; 2022():4322404. PubMed ID: 35531474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study.
    Yu D; Wang Z; He T; Yang L
    Front Surg; 2022; 9():842828. PubMed ID: 35647008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study.
    Yan Y; Li H; Wu S; Wang G; Luo H; Niu J; Cao L; Hu X; Xu H; Jia W; Sun Y; Yao Y; Chen W; Ke L; Hu B; Ji C; Sun Y; Chen J; Li M; He Y
    Ann Transl Med; 2022 Feb; 10(4):205. PubMed ID: 35280426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Third-Line Apatinib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer Patients: A Multicenter, Retrospective, Cohort Study.
    Fan W; Ding J; Zhong W
    Tohoku J Exp Med; 2023 May; 260(1):13-20. PubMed ID: 36696982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apatinib plus chemotherapy is associated with an improved tumor response, survival and tolerance compared with chemotherapy alone for advanced lung adenocarcinoma treatment.
    Ye H; Yu W; Ni Y; Bao X; Zhang X; Li Y; Chen A; Li J; Zheng L
    Oncol Lett; 2024 May; 27(5):194. PubMed ID: 38495832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy, safety, and beneficiary population of angiogenesis inhibitor apatinib plus chemotherapy in recurrent platinum-resistant ovarian cancer patients: A comparative cohort study.
    Wu C; Yan J; Wu Y
    J Obstet Gynaecol Res; 2024 Jun; ():. PubMed ID: 38839575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 20. Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy.
    Lin JX; Tang YH; Lin GJ; Ma YB; Desiderio J; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Zheng CH; Parisi A; Truty MJ; Huang CM
    JAMA Netw Open; 2022 Apr; 5(4):e225557. PubMed ID: 35363268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.